Lung Disease Treatment, 200,000 Additional Market Potential

On March 23, Insmed Inc. (INSM) announced positive topline results from its Phase 3b ENCORE study of ARIKAYCE (amikacin liposome inhalation suspension) in patients with nontuberculous mycobacteria (MAC) lung disease. The trial met its primary and secondary endpoints—including improvement in respiratory symptom scores and culture conversion—without any new safety signals. Based on these data, the company plans to submit a supplemental New Drug Application (sNDA) to the U.S. FDA and a submission to Japan’s PMDA in the second half of 2026.

These results raise expectations that ARIKAYCE’s indication could expand from the current roughly 30,000 refractory MAC patients to some 200,000 newly diagnosed MAC lung disease patients in the U.S. and Japan.

In late March and early April, Insmed’s Chief Legal Officer and Chief Operating Officer exercised stock options under pre-established Rule 10b5-1 trading plans and sold an equivalent number of shares, disclosing transactions valued at several million dollars (several billion Korean won).

In its February 19 release of fourth-quarter and full-year 2025 financial results, the company reported ARIKAYCE sales and provided a progress update on the U.S. commercialization of brensocatib (marketed as BRINSUPRI) for non-cystic fibrosis bronchiectasis, following its 2025 U.S. approval. Insmed also outlined additional clinical milestones expected in 2026 and detailed plans for its rare pulmonary disease and gene therapy pipeline.

Headquartered in New Jersey, Insmed is a biopharmaceutical company focused on rare and serious diseases. Leveraging its inhaled liposome formulation technology, the company addresses chronic lung infections and bronchiectasis with ARIKAYCE and oral brensocatib, while expanding its portfolio through inhaled and gene therapy platforms.

Nontuberculous mycobacteria lung disease and non-cystic fibrosis bronchiectasis are difficult-to-treat respiratory conditions with limited therapeutic options. Both benefit from expedited regulatory review and orphan drug incentives. Successful label expansions in these areas could pair premium pricing with a larger patient population, creating a significant long-term revenue opportunity.